Fred D. Lublin

A major contributor to this article appears to have a close connection with its subject. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. Please discuss further on the talk page. (March 2015) (Learn how and when to remove this message)

Fred D. Lublin is an American neurologist and an authority on the treatment of multiple sclerosis. Along with colleagues at the National Multiple Sclerosis Society, his work redefined the clinical course definitions of MS.^[1]

Lublin is Director of the Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai Medical Center in New York and Saunders Family Professor of Neurology at Mount Sinai School of Medicine. He sits on the board of directors at both the National Multiple Sclerosis Society and MS Hope for a Cure and has been listed in "Who's Who in Frontiers of Science and Technology" and New York Magazine's "Best Doctors" issue every year since 2000.^[2][3][4]

According to his employer, in 2004, Lublin secured one of the largest grants ever given for MS research, a $25 million grant from the NIH, to study the benefits of combination drug therapy.^[5] He is a consultant to the National Institutes of Health and to pharmaceutical/biotech companies in all phases of drug development in preparation for presentation to the FDA and their advisory panels.

He is the author of numerous scientific publications including Defining the Clinical Course of Multiple Sclerosis: Results of an International Survey, one of the most frequently cited works in the field of multiple sclerosis.^[6]